BofA analyst Alec Stranahan raised the firm’s price target on Intellia Therapeutics (NTLA) to $19 from $17 and keeps a Neutral rating on the shares. The FDA has removed the clinical hold on the MAGNITUDE Phase 3 study in transthyretin amyloidosis-cardiomyopathy for nex-z, re-opening the “larger value driver in the franchise,” the analyst tells investors. Following the news, the firm increased its view of the probability of success in ATTR-CM to 55% from 38%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $48 from $54 at Canaccord
- Balancing Reduced Regulatory Risk and Ongoing Development Uncertainty: Rationale for Maintaining a Hold Rating
- Intellia Therapeutics price target raised to $15 from $12 at Wells Fargo
- Intellia Therapeutics price target raised to $30 from $25 at H.C. Wainwright
- Intellia Therapeutics price target raised to $28 from $21 at Citizens